Background: The value of carotid intervention is predicated on long-term survival for patients to derive a stroke prevention benefit. Randomized trials report no significant difference in survival after carotid endarterectomy (CEA) vs carotid artery stenting (CAS), whereas observational studies of "real-world" outcomes note that CEA is associated with a survival advantage. Our objective was to examine long-term mortality after CEA vs CAS using a propensity-matched cohort.
Carotid revascularization is one of the most common procedures performed by vascular surgeons for primary and secondary stroke prevention. Guidelines from the Society for Vascular Surgery as well as randomized controlled trials in both symptomatic and asymptomatic patients support intervening for appropriately selected individuals with carotid stenosis. [1] [2] [3] [4] [5] Revascularization is associated with a stroke reduction benefit compared with medical therapy. [1] [2] [3] [4] [5] [6] [7] However, the perioperative period itself is associated with a risk of stroke, and because of this, patients may not realize a stroke prevention benefit for months or years after surgery. [1] [2] [3] [4] [5] [6] [7] Therefore, the ultimate value of carotid intervention is predicated on long-term survival. The difference in mortality between the two primary methods of carotid revascularization, carotid endarterectomy (CEA) and carotid artery stenting (CAS), has been a topic of debate. Randomized trials demonstrate that there is no difference in survival between the two procedures, but these results may not be generalizable, given the carefully selected patients included in the trials. 6, 8 Observational studies, which may be more representative of "real-world" results, report different findings from randomized trials, demonstrating superior longterm survival after CEA compared with CAS. [9] [10] [11] [12] However, these observational studies have been limited by use of administrative data for risk adjustment or registry data, often with little long-term follow-up. The objective of this study was to better describe the relative mortality of CEA compared with CAS using crude, adjusted, and propensity-matched analyses. We leveraged data from the Vascular Quality Initiative (VQI) registry that was linked to Medicare claims to allow precise risk adjustment using granular registry information from the VQI and the longest duration of follow-up available using Medicare claims.
METHODS
Data sources. We used registry data from the VQI to identify patients who had undergone CEA or CAS at participating centers across the United States and Canada. 13 We then obtained long-term data on Medicare-eligible patients using the Medicare Denominator File. 14 We linked patients in the VQI to their respective Medicare claims file directly using unique patient-level identifiers. Our analytic cohort was then taken from this combined data set.
Inclusion, exclusion, and sampling. Patients were eligible for inclusion if they had undergone CEA or CAS between January 1, 2003, and December 31, 2013. We excluded patients from centers that performed fewer than 10 carotid revascularization procedures annually. Data from these centers may confound results with a differential learning effect in the surgeon's ability to perform the procedures. [15] [16] [17] Such learning effects can be particularly pronounced when the procedural volume is small, whereas this effect is likely to have ceased across centers that perform a large number of procedures. [15] [16] [17] For subgroup analyses on symptomatic and asymptomatic patients, we further excluded patients from centers that performed fewer than 10 procedures for either group. For this reason, the number of patients included in the overall analysis slightly exceeds the number included in the subgroup analyses.
Primary exposure and outcome. Our primary exposure of interest was procedure type, CEA vs CAS. Patients who underwent more than one carotid procedure on the same day were assigned according to the first operation performed on them. Patients who underwent repeated procedures during the study period were assigned according to the index operation.
Our primary outcome of interest was all-cause mortality. We assessed mortality for all included patients, with the at-risk period beginning on the day of surgery. We counted death during surgery as survival to 0.1 day.
We used mortality information from the Medicare Denominator File for Medicare-eligible patients who were successfully linked to their respective Medicare claims file (92% CEA and 90% CAS patients were linked). We used the VQI to assess mortality for all remaining patients.
Statistical analysis. We assessed our primary outcome in a series of ways. First, we calculated the unadjusted mortality rates after CEA and CAS using Kaplan-Meier estimation. We then compared the hazard ratio (HR) of relative mortality between CEA and CAS using three different Cox regression analyses. The crude HR of mortality between the two procedures was determined using a model in which the treatment procedure was the only predictor; the only difference between this analysis and the Kaplan-Meier analysis is that the Cox model enforces the proportional hazards assumption. 18 Next, we calculated the HR after adjustment for known confounding variables. Summary measures for the patients' characteristics included in the risk-adjusted regression model are included in Table I .
For the third Cox model analysis, we created a propensity-matched cohort balanced in baseline covariates. We used the known confounding variables in Table I to create a logistic regression model in which the dependent variable was the treatment procedure (CEA vs CAS). We then calculated the probability (propensity score) of undergoing CEA for each patient. 19 We matched patients who underwent CEA with similar patients who underwent CAS. We then compared the relative mortality between CEA and CAS by calculating the HR using Cox regression to account for censoring. We report continuous variables as means with standard deviations and categorical variables as percentages as appropriate. We used the unpaired Student t-test to compare continuous data and c 2 analysis to compare categorical data. We performed all statistical analyses using R version 3.3.2 software (R Foundation for Statistical Computing, Vienna, Austria). Recommendation: This study suggests that patients undergoing CEA had a survival advantage over those who received carotid artery stenting.
ARTICLE HIGHLIGHTS
Human subjects protection. All data were collected under the auspices of an Agency for Healthcare Research and Quality-designated Patient Safety Organization. This study was approved by the Committee for the Protection of Human Subjects at Dartmouth. All patients' personal health information was protected, records and outcomes were deidentified, and no testing or procedures were required for this study. Thus, the need for specific consent was waived.
RESULTS
Cohort characteristics. We found 33,650 patients who met inclusion criteria during the study interval (Table I) . This represented 29,235 patients undergoing CEA and 4415 undergoing CAS. The mean follow-up was 5.1 years (standard deviation, 2.5 years). Patients undergoing CEA were older (CEA, 70.2 years; CAS, 69.3 years; P < .001), more likely to be female (CEA, 40.2%; CAS, 37.1%; P < .001), and more likely to be of white race (CEA, 93.9%; CAS, 90.7%; P < .001). The two groups were also significantly different in most clinical characteristics. Those undergoing CEA were more likely to have their procedure performed on an elective basis (CEA, 86.7%; CAS, 83.0%; P < .001), less likely to be symptomatic at presentation (CEA, 38.3%; CAS, 48.3%; P < .001), and less likely to be taking a P2Y 12 inhibitor (CEA, 24.6%; CAS, 76.7%; P < .001) and had fewer comorbidities.
Given these differences, we used propensity score matching to generate 4261 matched pairs comprising a CEA patient and a CAS patient (Table I) . These groups were well matched in all baseline characteristics (P > .1), with the exception of a small difference in aspirin use (CEA, 83.1%; CAS, 85.3%; P ¼ .006) and a nearly significant difference in the proportion of patients with coronary disease (CEA, 37.2%; CAS, 35.4%; P ¼ .083). Given the infrequency with which hemodialysis patients were found in the original cohort (CEA, 1.1%; CAS, 0.1%), very few patients on hemodialysis were included in the propensity-matched cohort (CEA, 0.1%; CAS, 0.1%; P ¼ 1).
Mortality. The unadjusted Kaplan-Meier estimated mortality rate was lower for CEA at both 5 years (CEA, In our crude and adjusted risk models, the HR of relative mortality was lower for CEA in all analyses performed (Table II) . For example, the crude HR of mortality for CEA vs CAS was 0.75 (95% CI, 0.70-0.81) for the entire cohort, indicating that patients who underwent CEA were 25% less likely to die before those who underwent CAS. Adjustment for baseline characteristics minimally changed this protective effect, with an adjusted HR of mortality for CEA vs CAS of 0.75 (95% CI, 0.69-0.82). This finding persisted among the propensity-matched cohort, with an HR of mortality for CEA vs CAS of 0.76 (95% CI, 0.69-0.85).
The apparent protective effect of CEA relative to CAS on mortality was also evident on a subgroup analysis stratified by presenting symptoms. Interestingly, whereas this effect was present across all subgroups, it was most pronounced in patients with symptomatic stenosis. In absolute terms, the HR of mortality for symptomatic patients selected for CEA over CAS was 11% lower than the HR for their asymptomatic counterparts (symptomatic adjusted HR, 0. 
DISCUSSION
We found that among a large observational cohort of patients who underwent carotid revascularization, those who underwent CEA demonstrated a long-term survival advantage relative to those who underwent CAS. This finding was present in our crude model and did not diminish with risk adjustment or risk balancing through propensity matching. The protective effect of CEA was also observed in a subgroup analysis stratified by the presence of focal neurologic symptoms at the time of presentation and was most prominent in patients who were symptomatic.
Our findings complement those of previous investigators who used a variety of observational data sets. Using the National Inpatient Sample, both McPhee et al 9 and
Giles et al 10 have documented increased perioperative mortality rates for patients who undergo CAS relative to those who undergo CEA. Furthermore, Giles et al 10 demonstrated that this effect is persistent in a comparative analysis of high-risk operative candidates. A survival advantage for patients undergoing CEA has also been documented by Wang et al 11 using 1-year mortality data from Medicare claims. Last, using data from the Vascular Study Group of New England, Nolan et al 12, 20 found that mortality is elevated for symptomatic patients undergoing CAS relative to those undergoing CEA. Our use of Medicare claims information adds important long-term results to assist in defining the relative mortality between CEA and CAS. The consistency of our findings strengthens the results of previous investigators and likely indicates that the relative mortality derived from observational data sets is in favor of patients who undergo CEA. In contrast to the findings of the observational studies described, randomized trials comparing mortality after the two procedures have documented no difference in all-cause mortality. 6, 8 Whereas the Carotid Revascularization Endarterectomy vs Stenting Trial (CREST) investigators did not report all-cause mortality alone in their long-term results, they noted no significant difference in their primary composite outcome of periprocedural death, stroke, or myocardial infarction or long-term ipsilateral stroke despite providing estimates out to 10 years. 7 Although these trials may not have been powered to detect a difference in all-cause mortality, each reported a P value of >.2 for the comparison between CEA and CAS, indicating that the null finding remained consistent across investigations.
Our findings may provide a reason for this apparent difference in mortality between observational studies and randomized trials. Although we found a protective effect on mortality for patients undergoing CEA vs CAS, this effect was different for symptomatic vs asymptomatic patients. In our adjusted analysis, symptomatic patients undergoing CEA were 31% less likely to die than their counterparts who underwent CAS. Conversely, asymptomatic patients were only 20% less likely to die, with a CI extending close to the null, a finding similar to shorter term results observed by past investigators. 12 Patients with symptomatic stenosis are inherently more complex, as evidenced by the higher burden of comorbidities noted in our study. This makes categorizing risk factors into easily quantifiable covariates to use in risk adjustment methods or propensity matching difficult. In fact, a subjective assessment by surgeons of the patient's "fitness" for surgery has been shown to be an independent predictor of outcomes. 21 These factors can cause patients to be exposed to surgeon-level selection bias, a confounder that is difficult to adjust for in statistical models. 22 Whereas propensity matching decreased the apparent difference in the HR between asymptomatic and symptomatic patients, the protective effect of CEA persisted. Therefore, the differential treatment effect of CEA on mortality for symptomatic vs asymptomatic patients in our study may be due to unmeasured, or unmeasurable, confounding factors. More robust analytic techniques that can account for both measurable and unmeasurable confounding may offer further insights into these differences or lack of differences. Our study has limitations. First, it is a retrospective analysis. However, we believe that the use of retrospective observational registry data allows the evaluation of outcomes in real-world clinical practice. Second, we did not evaluate the rate of long-term stroke, as this outcome has been shown to be unreliable in administrative data sets by previous investigators. 23, 24 Medicare data are based on billing codes and are subject to inherent limitations when used to identify clinical events. The identification of true stroke events from Medicare data is an area of active investigation for our research group. In addition, the determination of stroke and other clinical events and subsequently the ultimate cause of death is often not reliable. Therefore, although we are able to quantify the relative mortality between CEA and CAS, we are unable to comment on the cause of death in such cases. Third, analytic methods capable of accounting for unmeasured confounding in observational studies, such as instrumental variables, become biased when applied to time-to-event outcomes, such as mortality, and because of this, we are unable to control for unmeasured confounding in our analyses. 25 Last, because our propensity-matched cohort included very few patients on hemodialysis, results may not apply to these patients.
CONCLUSIONS
In an observational study of >33,000 patients, we found that those who underwent CEA were conferred a survival advantage relative to those who underwent CAS. This finding was robust among a balanced propensitymatched cohort of >4000 pairs of patients. This contrasts with randomized trials that demonstrate no difference in survival between CEA and CAS. These differences between registry-based observational analyses and clinical trial data may be a result of true differences, 
